$HCIL
Hongchang International Co., Ltd Stock $hcil

$hcil Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121390023038835 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue		$10.12K	$49.99K
YoY Change		-33.15%	176.49%
Cost Of Revenue	$3.011K	$1.161K	$17.76K
YoY Change	-29.57%	-79.01%	184.16%
Gross Profit	-$3.011K	$8.960K	$32.23K
YoY Change	-129.78%	-6.76%	172.44%
Gross Profit Margin		88.53%	64.47%
Selling, General & Admin		$157.5K	$153.5K
YoY Change		166.31%	353.05%
% of Gross Profit		1757.48%	476.39%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$22.70K
YoY Change
% of Gross Profit		253.38%
Operating Expenses	$146.3K	$157.5K	$153.5K
YoY Change	38.76%	166.26%	353.19%
Operating Profit	-$149.3K	-$148.5K	-$121.3K
YoY Change	56.64%	199.83%	450.16%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net		$131.00	$110.00
YoY Change		555.0%	-466.67%
Pretax Income	-$138.4K	-$148.4K	-$121.2K
YoY Change	45.28%	199.63%	448.91%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$138.4K	-$148.4K	-$121.2K
YoY Change	45.28%	199.63%	448.91%
Net Earnings / Revenue		-1466.03%	-242.45%
Basic Earnings Per Share	$0.00	$0.00
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	1.032B shares	1.032B shares
Diluted Shares Outstanding	415.6M shares	1.032B shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments		$29.21K	$11.43K
YoY Change		624.81%
Cash & Equivalents	$6.082K	$29.21K	$11.43K
Short-Term Investments
Other Short-Term Assets		$3.140K	$3.130K
YoY Change		-7.92%
Inventory	$367.00
Prepaid Expenses
Receivables
Other Receivables	$23.02K	$24.20K	$17.85K
Total Short-Term Assets	$32.45K	$56.55K	$32.40K
YoY Change	-14.44%	66.48%	-13.3%
LONG-TERM ASSETS
Property, Plant & Equipment		$192.6K	$0.00
YoY Change		447.07%
Goodwill
YoY Change
Intangibles			$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$22.50K	$13.53K
YoY Change
Total Long-Term Assets	$191.2K	$206.1K
YoY Change	1333.72%	485.36%
TOTAL ASSETS
Total Short-Term Assets	$32.45K	$56.55K	$32.40K
Total Long-Term Assets	$191.2K	$206.1K
Total Assets	$223.6K	$262.7K	$32.40K
YoY Change	336.23%	279.67%	-65.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$15.51K	$16.21K	$16.15K
YoY Change	-6.47%	-6.87%	-6.95%
Accrued Expenses	$126.2K	$183.4K	$285.1K
YoY Change	-67.1%	-13.03%	0.43%
Deferred Revenue	$416.6K	$438.0K	$434.9K
YoY Change	-7.02%		-7.82%
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.375M	$2.276M	$2.005M
YoY Change	22.46%	17.82%	5.34%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$112.2K
YoY Change
Total Long-Term Liabilities	$92.64K	$112.2K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.375M	$2.276M	$2.005M
Total Long-Term Liabilities	$92.64K	$112.2K
Total Liabilities	$2.467M	$2.389M	$2.005M
YoY Change	27.24%	37.42%	5.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$20.23M	-$20.04M	-$19.89M
YoY Change	2.33%		1.35%
Common Stock	$103.2K	$1.032M	$1.032M
YoY Change	-90.0%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.012M	-$1.857M	-$1.757M
YoY Change
Total Liabilities & Shareholders Equity	$223.6K	$262.7K	$32.40K
YoY Change	336.23%	279.67%	-65.36%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$138.4K	-$148.4K	-$121.2K
YoY Change	45.28%	199.63%	448.91%
Depreciation, Depletion And Amortization		$22.70K
YoY Change
Cash From Operating Activities		-$292.5K	-$187.9K
YoY Change		-600.33%	676.29%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change
Cash From Investing Activities			$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		$310.3K	192.4K
YoY Change		-590.58%	344.01%
NET CHANGE
Cash From Operating Activities		-$292.5K	-187.9K
Cash From Investing Activities			0.000
Cash From Financing Activities		$310.3K	192.4K
Net Change In Cash		$17.78K	4.450K
YoY Change		-471.23%	-76.73%
FREE CASH FLOW
Cash From Operating Activities		-$292.5K	-$187.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Heyu Biological Technology Corp
CY2023Q1	hybt	Selling Expenses SellingExpenses		usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies		usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies		usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets		usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities		usd
CY2023Q1	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent		usd
CY2022Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent		usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Baotuo Building
CY2023Q1	dei	Entity Address Address Line3 EntityAddressAddressLine3	617 Sishui Street
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Xiamen City
CY2023Q1	dei	Entity Address Country EntityAddressCountry	CN
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	361009
CY2023Q1	dei	City Area Code CityAreaCode	(86)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	158 5924 0902
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1032466000	shares
CY2023Q1	us-gaap	Cash Cash	29210	usd
CY2022Q4	us-gaap	Cash Cash	11428	usd
CY2023Q1	hybt	Other Receivables Net OtherReceivablesNet	24201	usd
CY2023Q1	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	3143	usd
CY2022Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	3131	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	56554	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	32404	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	192574	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13531	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	206105	usd
CY2023Q1	us-gaap	Assets Assets	262658	usd
CY2022Q4	us-gaap	Assets Assets	32404	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	16205	usd
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-26731
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-0627910
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	Room 1901
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	16150	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	183367	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	285081	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	438028	usd
CY2022Q4	hybt	Other Receivables Net OtherReceivablesNet	17845	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2276397	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	434890	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	140	usd
CY2023Q1	hybt	Operating Lease Liability Current Portion OperatingLeaseLiabilityCurrentPortion	57664	usd
CY2023Q1	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1581133	usd
CY2022Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1268749	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2005010	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	112215	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	112215	usd
CY2023Q1	us-gaap	Liabilities Liabilities	2388612	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2005010	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1032466000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1032466000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1032466000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1032466000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	1032466	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1032466	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17149050	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17149050	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-148377	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-49515	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	6309	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-3158	usd
CY2023Q1	hybt	Increase Decrease Operating Lease Rightofuse Asset IncreaseDecreaseOperatingLeaseRightofuseAsset	193252	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-52298	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20035077	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19886700	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1856561	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1757482	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	-269393	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-215124	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2125954	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1972606	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	262658	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32404	usd
CY2023Q1	us-gaap	Revenues Revenues	10121	usd
CY2022Q1	us-gaap	Revenues Revenues	15135	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	1161	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	5532	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	8960	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	9603	usd
CY2022Q1	hybt	Selling Expenses SellingExpenses	67	usd
CY2023Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	157468	usd
CY2022Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	59067	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	157468	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	59134	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-148508	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-49531	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	131	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	16	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-148377	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-49515	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-148377	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-49515	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-148377	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-49515	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	4971	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	38455	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-153348	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-87970	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-54269	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-34195	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-99079	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-53775	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1032466000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1032466000	shares
CY2022Q1	hybt	Increase Decrease Operating Lease Rightofuse Asset IncreaseDecreaseOperatingLeaseRightofuseAsset	-20971	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	13578	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	41	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-102772	usd
CY2022Q1	hybt	Advances From Customer AdvancesFromCustomer	-1263	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-141	usd
CY2023Q1	hybt	Increase Decrease Lease Liability IncreaseDecreaseLeaseLiability	-170476	usd
CY2022Q1	hybt	Increase Decrease Lease Liability IncreaseDecreaseLeaseLiability	21680	usd
CY2022Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	16039	usd
CY2023Q1	hybt	Advances From Customer AdvancesFromCustomer	1460	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-292493	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29723	usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	310290	usd
CY2022Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	32991	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	310290	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32991	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-15	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3557	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17782	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-289	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11428	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4323	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29210	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4034	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1809852	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	3556	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-49515	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1862923	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1972606	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4971	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-148377	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2125954	usd
CY2019Q1	hybt	Equity Interests EquityInterests	0.90	pure
CY2020Q1	hybt	Gross Proceeds Percentage GrossProceedsPercentage	0.02	pure
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however, actual results could differ from these estimates. Significant estimates include the allowance for doubtful accounts, impairment assessments of goodwill, valuation of deferred tax assets, rebilling collections and certain accrued liabilities such as contingent liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	hybt	Operating Lease Right Of Uses Asset OperatingLeaseRightOfUsesAsset	192574	usd
CY2023Q1	hybt	Office Space Lease OfficeSpaceLease	192574	usd
CY2023Q1	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	6.8717	pure
CY2022Q4	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	6.8983	pure
CY2023Q1	hybt	Shares Of Authorized SharesOfAuthorized	2000000000	shares
CY2022	hybt	Shares Of Authorized SharesOfAuthorized	2000000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	hybt	Number Of Shares Issued And Outstanding NumberOfSharesIssuedAndOutstanding	1032466000	shares
CY2022Q4	hybt	Number Of Shares Issued And Outstanding NumberOfSharesIssuedAndOutstanding	1032466000	shares
CY2023Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-148377	usd
CY2022Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-49515	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1032466000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1032466000	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20035077	usd
CY2023Q1	hybt	Working Capital Deficit WorkingCapitalDeficit	2219843	usd
CY2023Q1	hybt	Cash And Cash Equivalents CashAndCashEquivalents	29210	usd
CY2022Q4	hybt	Cash And Cash Equivalents CashAndCashEquivalents	11428	usd
CY2023Q1	us-gaap	Deposits Deposits	1333	usd
CY2022Q4	us-gaap	Deposits Deposits	13954	usd
CY2023Q1	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	22868	usd
CY2022Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3891	usd
CY2023Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	24201	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	17845	usd
CY2023Q1	hybt	Schedule Of Advances To Suppliers Table Text Black ScheduleOfAdvancesToSuppliersTableTextBlack	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Purchases of scientific research equipment</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">3,143</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">3,131</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,143</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,131</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	3143	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	3131	usd
CY2023Q1	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	3143	usd
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	3131	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	192574	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.043	pure
CY2023Q1	hybt	Operating Leases Future Minimum Payment Due Current OperatingLeasesFutureMinimumPaymentDueCurrent	47792	usd
CY2023Q1	hybt	Operating Leases Future Minimum Payments Due In Two Year OperatingLeasesFutureMinimumPaymentsDueInTwoYear	63722	usd
CY2023Q1	hybt	Operating Leases Future Minimum Payments Due In Three Year OperatingLeasesFutureMinimumPaymentsDueInThreeYear	63722	usd
CY2023Q1	hybt	Operating Leases Future Minimum Payments Due In Four Year OperatingLeasesFutureMinimumPaymentsDueInFourYear	5310	usd
CY2023Q1	hybt	Operating Leases Future Minimum Payment Due OperatingLeasesFutureMinimumPaymentDue	180546	usd
CY2023Q1	hybt	Less Imputed Interest LessImputedInterest	10667	usd
CY2023Q1	hybt	Present Value Of Lease Liabilities PresentValueOfLeaseLiabilities	169879	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	438028	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	434890	usd
CY2019Q4	hybt	Cash And Securitie Segregated Under Commodity Exchange Act Description CashAndSecuritieSegregatedUnderCommodityExchangeActDescription	Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of the Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month.
CY2023Q1	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	134697	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	155078	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	48670	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	130003	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	183367	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	285081	usd
CY2023Q1	us-gaap	Other Receivable After Allowance For Credit Loss Noncurrent OtherReceivableAfterAllowanceForCreditLossNoncurrent	1581133	usd
CY2022Q4	us-gaap	Other Receivable After Allowance For Credit Loss Noncurrent OtherReceivableAfterAllowanceForCreditLossNoncurrent	1268749	usd
CY2023Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent		usd
CY2022Q4	hybt	Operating Lease Liability Current Portion OperatingLeaseLiabilityCurrentPortion		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent		usd
CY2023Q1	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges		usd
CY2022Q1	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges		usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1032466000	shares
CY2023Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001086303

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001213900-23-038835-index-headers.html	Edgar Link	pending
0001213900-23-038835-index.html	Edgar Link	pending
0001213900-23-038835.txt	Edgar Link	pending
0001213900-23-038835-xbrl.zip	Edgar Link	pending
f10q0323ex31-1_heyubiolog.htm	Edgar Link	pending
f10q0323ex31-2_heyubiolog.htm	Edgar Link	pending
f10q0323ex32-1_heyubiolog.htm	Edgar Link	pending
f10q0323ex32-2_heyubiolog.htm	Edgar Link	pending
f10q0323_heyubiolog.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hybt-20230331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
hybt-20230331_cal.xml	Edgar Link	unprocessable
hybt-20230331_def.xml	Edgar Link	unprocessable
hybt-20230331_lab.xml	Edgar Link	unprocessable
hybt-20230331_pre.xml	Edgar Link	unprocessable
f10q0323_heyubiolog_htm.xml	Edgar Link	completed
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HCIL
Hongchang International Co., Ltd Stock $hcil

2023 Q2 Form 10-Q Financial Statement

#000121390023038835 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCIL Hongchang International Co., Ltd Stock $hcil

2023 Q2 Form 10-Q Financial Statement

#000121390023038835 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCIL
Hongchang International Co., Ltd Stock $hcil